Semaglutide
InjectionWeight Loss
InjectionWeight LossIn stock
Wegovy® injection
Branded semaglutide approved specifically for chronic weight management, titrated up to 2.4 mg weekly. Run a Wegovy®-aware weight-loss program with intake, billing, refill, and pharmacy workflows wired into one backend.
Dose
Once weekly
Avg. loss · 68 wks
−14.9%
Format
Weekly subcutaneous pen injection
Dose range
0.25 mg to 2.4 mg (HD: 7.2 mg)
Rx required
Yes, licensed provider review
Indication
Chronic weight management
About the medication
Semaglutide engineered for chronic weight management
Wegovy® is Novo Nordisk's branded once-weekly semaglutide approved specifically for chronic weight management. In the STEP 1 trial, adults with obesity lost an average of 14.9% of body weight over 68 weeks on the 2.4 mg dose. A higher-dose Wegovy® HD (7.2 mg) is also FDA approved as of March 2026.
- Same molecule as Ozempic® but titrated higher (2.4 mg vs 2.0 mg, and 7.2 mg HD)
- Approved for chronic weight management in adults with obesity or overweight + comorbidity
- Available as an oral tablet companion (see Wegovy® tablet) for non-injection-preferring patients
- Established weight-loss outcomes data from the STEP trial program
Mechanism
GLP-1 receptor agonist, appetite and satiety pathway
Delivery
Pre-filled single-use pen, once weekly subcutaneous
Onset
Appetite changes within days, weight loss builds over 12 to 68 weeks
Oversight
Every order routed through a licensed provider review
Expected results
Strong weight outcomes from the higher-dose semaglutide brand
Based on the STEP 1 trial (68 weeks, 2.4 mg weekly). Real-world outcomes depend on titration adherence, lifestyle changes, and individual response.
14.9%
Avg. total body weight loss
at 68 weeks, 2.4 mg weekly
86%
Patients losing ≥5%
of completers in STEP 1
50%
Patients losing ≥15%
of completers in STEP 1
Mean change in body weight
% change from baseline · weeks 0–68
Wegovy® 2.4 mgPlacebo
At week 68
−14.9%
Wegovy® 2.4 mg
At week 68
−2.4%
Placebo
Net difference
−12.5 pts
vs. placebo
Illustrative, based on published STEP 1 outcomes for Wegovy® 2.4 mg. Wegovy® HD 7.2 mg outcomes are based on separate trials and may differ.
Dosing protocol
Standard titration schedule
Wegovy® labeling escalates over 16 to 20 weeks from 0.25 mg to the 2.4 mg maintenance dose, with the option to step up further to 7.2 mg (Wegovy® HD) where appropriate.
- 1Weeks 1–40.25 mgInitiation, GI side-effect tolerance
- 2Weeks 5–80.5 mgFirst up-titration
- 3Weeks 9–121.0 mgTherapeutic ramp
- 4Weeks 13–161.7 mgPre-maintenance
- 5Week 17+2.4 mgStandard maintenance dose
- 6Optional7.2 mgWegovy® HD, higher-dose maintenance per Mar 2026 approval
The Turbopills stack for this program
Everything you need to run a Wegovy® program
Pick the pieces you want. Use your own brand, your own providers, your own price, powered by a single, compliant backend.
Product website & ad landing pages
Turbopills AI Studio — ad images & videos
BetaProvider review & e-Rx
Pharmacy order routing
Refills & auto-ship
Experiments & A/B tests
BetaReady to launch
Ship a Wegovy® program in weeks, not quarters.
The platform ships the intake flow, billing, subscriptions, refill workflows, and the operator console your team works in. Bring your licensed providers and pharmacy partners; we wire everything into one backend so you launch in weeks, not quarters.
Marketing and educational content only. Clinical details on this page are summarized from publicly available sources to help operators scope a program — they are not medical advice, dosing instructions, or a recommendation for any individual patient. Real patient care requires a licensed provider and a compliant pharmacy partner; Turbopills provides the software that helps brands run the program around them.
Trademark notice. Wegovy® is a registered trademark of Novo Nordisk A/S. Turbopills is not affiliated with, endorsed by, or sponsored by Novo Nordisk. References to the brand are for educational and operator-scoping purposes only.
Related
